[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 688,615
  • Shares Outstanding, K 52,566
  • Annual Sales, $ 60 K
  • Annual Income, $ -78,260 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 0.83
  • Price/Sales 12,125.82
  • Price/Cash Flow N/A
  • Price/Book 5.32

Options Overview Details

View History
  • Implied Volatility 107.99% (+13.00%)
  • Historical Volatility 121.56%
  • IV Percentile 14%
  • IV Rank 13.07%
  • IV High 506.06% on 05/04/26
  • IV Low 48.13% on 09/04/25
  • Expected Move (DTE 11) 0.43 (3.24%)
  • Put/Call Vol Ratio 22.00
  • Today's Volume 69
  • Volume Avg (30-Day) 1,680
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 52,302
  • Open Int (30-Day) 72,602
  • Expected Range 12.68 to 13.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.68
  • Number of Estimates 5
  • High Estimate $-0.52
  • Low Estimate $-0.94
  • Prior Year $-1.92
  • Growth Rate Est. (year over year) +64.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.89 +1.63%
on 06/05/26
24.27 -46.02%
on 05/07/26
-3.16 (-19.43%)
since 05/05/26
3-Month
12.51 +4.72%
on 04/29/26
24.27 -46.02%
on 05/07/26
-4.48 (-25.48%)
since 03/05/26
52-Week
4.06 +222.66%
on 06/06/25
24.27 -46.02%
on 05/07/26
+8.77 (+202.54%)
since 06/05/25

Most Recent Stories

More News
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Announces Pricing of $375 Million Public Offering

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Purchases Optional Milestone Buyout

WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for...

AVTX : 13.10 (-3.75%)
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026 Cash, cash equivalents and short-term investments...

AVTX : 13.10 (-3.75%)

Business Summary

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is...

See More

Key Turning Points

3rd Resistance Point 14.48
2nd Resistance Point 14.12
1st Resistance Point 13.61
Last Price 13.10
1st Support Level 12.74
2nd Support Level 12.38
3rd Support Level 11.87

See More

52-Week High 24.27
Fibonacci 61.8% 16.55
Fibonacci 50% 14.16
Last Price 13.10
Fibonacci 38.2% 11.78
52-Week Low 4.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.